Skip to content

Sight Sciences, Inc. SGHT Non-cash interest expense

Non-cash interest expense at other companies

Bausch + Lomb logo
Bausch + LombBLCO
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS

Other financials

Income statement

See full
Revenue$19.7M+12.5%
Gross profit$17.0M+12.5%
Operating income-$12.4M+10.4%
Net income-$13.0M+8.3%
EPS (diluted)-$0.24+14.3%

Balance sheet

See full
Cash & equivalents$85.0M-21.9%
Total debt$40.9M+1.1%
Total equity$53.9M-30.6%
Total assets$109.7M-15.4%

Cash flow

See full
Operating cash flow-$7.0M+39.4%
CapEx$60.0K
Free cash flow-$7.1M+38.9%

Valuation

See full
Market cap$294.9M+35.0%
Enterprise value$250.83M+59.0%
P/S3.7×+0.8×

Profitability

See full
Gross margin86.2%+0.5pp
Operating margin-44.8%-10.2pp
Net margin-46.8%-9.6pp
FCF margin-31.9%+0.2pp

Returns & leverage

See full
Return on equity-56.6%+4.3pp
Debt / equity0.8×+0.2×
Current ratio5.9×-4.6×

Where this comes from

Reported directly by Sight Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: Sight Sciences, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sight Sciences, Inc.'s non-cash interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sight Sciences, Inc.'s non-cash interest expense?
Sight Sciences, Inc. (SGHT) reported non-cash interest expense of $233K in Q1 2026.
How has Sight Sciences, Inc.'s non-cash interest expense changed year-over-year?
Sight Sciences, Inc.'s non-cash interest expense increased by 2.2% year-over-year, from $228K to $233K.
What is the long-term trend for Sight Sciences, Inc.'s non-cash interest expense?
Over 4 years (2021 to 2025), Sight Sciences, Inc.'s non-cash interest expense has grown at a 7.7% compound annual growth rate (CAGR), from $701K to $944K.